From April 1, 2024 to April 17, 2024, the company has repurchased 500 shares, representing 0.000034% for CNY 0.007505 million. With this, the company has completed the repurchase of 7,023,600 shares, representing 0.48% for CNY 99.99 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.05 CNY | -0.70% | -4.64% | +16.22% |
06-17 | Huahai Pharmaceutical's Subsidiary Terminates Listing Guidance | MT |
06-14 | Zhejiang Huahai Pharmaceutical Co., Ltd.(SHSE:600521) dropped from SSE 180 Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.22% | 3.4B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.